insights_auto
Pse është rritur AZN 2,85%?
Zhytu më thellëchevron_right
AZN:NYSE
AstraZeneca PLC (US)
166,68 US$
arrow_upward
+2,85%(+4,62) 1D
165,85 US$
arrow_downward
-0,50% (-0,83)todayPara orarit të tregut
Mbyllur: 15 tet, 4:00:03 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për AZN...
Hap
167,69 US$
I lartë
169,81 US$
I ulët
166,49 US$
Kapitalizimi i tregut
261,56 mld
Vëllimi mesatar
2,93 mln
Vëllimi
10,36 mijë
Dividendi
1,93%
Dividendi tremujor
0,81 US$
Data e ndërprerjes së dividendit
6 gush 2026
Raporti çmim/fitim
24,92
Maksimumi 52-javor
212,71 US$
Minimumi 52-javor
80,48 US$
Fitimet për aksion
6,69 US$
Beta
0,30
Aksionet në qarkullim
1,55 mld
Numri i punonjësve
96 mijë
Hap
167,69 US$
I lartë
169,81 US$
I ulët
166,49 US$
Kapitalizimi i tregut
261,56 mld
Vëllimi mesatar
2,93 mln
Vëllimi
10,36 mijë
Dividendi
1,93%
Dividendi tremujor
0,81 US$
Data e ndërprerjes së dividendit
6 gush 2026
Raporti çmim/fitim
24,92
Maksimumi 52-javor
212,71 US$
Minimumi 52-javor
80,48 US$
Fitimet për aksion
6,69 US$
Beta
0,30
Aksionet në qarkullim
1,55 mld
Numri i punonjësve
96 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
1 orë më parë
AstraZeneca announces USD 1.46 billion insitro deal: AstraZeneca stock trades at EUR 148.70
Yahoo Finance UK
·
3 orë më parë
While the market panics about the FTSE 100, Citi just raised its AstraZeneca target to £186
JournalArta
·
7 orë më parë
AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance
Reuters
·
10 orë më parë
AstraZeneca strikes $40 million AI drug discovery deal with insitro
Profili
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Rreth AstraZeneca PLC (US)
Drejtori ekzekutivPascal Soriot
Punonjësit96,1 mijë
Themeluar më6 pri 1999
SeliaKembrixh, Cambridgeshire, Mbretëria e Bashkuar
Sektori-
Uebsajtiastrazeneca.com